CoronaVac (SinoVac) - versus control - for COVID-19 prophylaxis (excluding children) pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

vaccine efficacy from randomization (ITT) 0.42 [0.33, 0.54]< 10%1 study (1/-)100.0 %NAnot evaluable crucial-
confirmed COVID (any severity) 0.49 [0.38, 0.64]< 10%1 study (1/-)100.0 %NAnot evaluable important-
hospitalization NaN [NaN, NaN]< 10%1 study (1/-)NaNNAnot evaluable important-
symptomatic Covid-19 0.16 [0.09, 0.29]< 10%2 studies (2/-)100.0 %NAnot evaluable important-
severe COVID-19 occurrence NaN [NaN, NaN]< 10%1 study (1/-)NaNNAnot evaluable non important-

AE of interest endpoints 00

immunogenicity (vaccines) endpoints 00

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.